Glooko’s Mobile Insulin Dosing System aims to make it easier and more effective for physicians and patients to titrate long-acting insulin between visits
Mountain View, California and Gothenburg, Sweden, February 14, 2018 — Glooko, the leader in diabetes data management, today announced its Mobile Insulin Dosing System (MIDS) has been cleared by the Food and Drug Administration for the titration of long-acting insulin for people with type 2 diabetes. Glooko’s MIDS is the first insulin titration application accessible through a unified diabetes management platform, which provides a complete program for diabetes management.
The system includes access to a patient’s blood glucose (BG) data directly from their glucose meter so people with diabetes (PWDs) do not have to manually enter their fasting blood glucose, and healthcare providers (HCPs) access accurate diabetes data in the MIDS module[1]. MIDS analyzes a patient’s fasting blood glucose levels and recommends insulin dose adjustments based on the HCP’s pre-configured treatment plan and/or published clinical guidelines so patients can quickly and easily get to their optimal insulin dose. To enhance adherence, MIDS includes customizable in-app reminders to check fasting blood glucose and to take insulin.
Poor understanding of insulin therapy by people with diabetes, combined with clinical inertia driven by a lack of knowledge, education and time, has negatively impacted the success of insulin therapy[2]. Less than 50% of PWDs on long-acting insulin have achieved their target glycemic outcomes[3]. At the same time, patient education and communication on insulin titration has proven clinical benefits[4].
While adherence to insulin therapy is sub-optimal, clinical inertia by physicians — resistance to initiate and/or escalate insulin therapy — is also a barrier to achieving glycemic control for PWDs. Although step-wise intensification of diabetes therapy is recommended by both national and international guidelines[5], physicians in the U.S. tend to delay the initiation of insulin therapy compared to physicians from other countries[6].
The prevalence of mobile technologies provides a way to support and educate patients on insulin in a continuous and contextual manner. With MIDS, Glooko has set out to ease and improve adherence to insulin therapy and drive overall better health outcomes among people with type 2 diabetes.
“Managing long-acting insulin can be a challenge for people with diabetes because it requires patients to regularly change their doses based on their own calculations using fasting glucose values. This can be daunting and unreliable,” said Dr. Michael Greenfield, Chief Medical Officer at Glooko.
He continued, “I am excited that Glooko can now offer MIDS, which helps clinicians support their patients in safely and rapidly attaining optimal glycemic levels. In a pre-market study, I used MIDS with my patients and was able to witness both improvements in glucose control and how happy patients were to have an easy tool to help them titrate their insulin dose on their mobile phones.”
Glooko invested in 18 months of close collaboration with clinical experts around the world to ensure MIDS is market-ready. Many rounds of user experience design reviews, human factors studies, pre-market programs and feedback sessions have culminated in the delivery of MIDS. Results, including some from these studies, can be found in an infographic recently presented at the Diabetes Technology Society meeting and available here.
To get a demonstration of MIDS or start to use MIDS with your patients or members, please click here to contact Glooko.
About Glooko
Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Our self-management mobile app automatically uploads data from devices including blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers — providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. We provide care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, we are used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com
©2018 Glooko, Inc. Glooko and Diasend are trademarks of Glooko, Inc. All rights reserved. PRM 0467 Rev A
[1] Kalergis, et al. (2006) Science Direct; Accuracy and Reliability of Reporting Self-monitoring of Blood Gluocse Results.
[2] Diabetes Care. 2010;33(2):240-5; Patient Prefer Adherence. 2008;2:87-95; Diabetes Med. 2012;29(5):682-9; Diabetes Care. 2005;28(1):78-83.
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889324/
[4] J Multidiscip Healthc. 2014;7: 267–282.
[5] Diabetes Educ. 2011;37(1):111-23; J Gen Intern Med. 2007;22(4):453-8.
[6] Diabetes Care. 2005;28(11):2673-9; Endocrine Practice: February 2016, Vol. 22, No. 2, pp. 151-161.
Report draws on 8.5 billion diabetes data points, one of the largest bodies of combined diabetes data in the world
Mountain View, California and Gothenburg, Sweden – February 5, 2018 – Glooko, the leader in diabetes data management, today released its annual, comprehensive diabetes report based on analysis of over 8.5 billion de-identified data points. The report observes trends based on information collected from more than 1.5 million people with diabetes (PWDs) globally and includes by-country views of glycemic trends, occurrences of hyperglycemia and hypoglycemia, and insulin usage.
“Glooko’s ability to understand diabetes patterns and trends globally is unique due to our ability to capture data from over 95% of the diabetes devices on the market, collecting information from more than 1.5 million PWDs. This year’s benchmark produced compelling behavioral insights about global diabetes populations, which can be used to better grasp the habits of people with diabetes,” said Dave Conn, Chief Commercial Officer of Glooko.
Notable findings in the report include:
- PWDs in Australia trend towards the highest average blood glucose (BG), averaging 194 mg/dL (a 1.9% increase in average BG compared to 2016 findings), while those in Belgium trend towards the lowest average BG with 156.8 mg/dL, a 0.8% decrease in average BG compared to 2016). In 2016, Canada had the highest average BG and Belgium had the lowest average BG;
- PWDs in the Netherlands experienced the highest frequency of hypoglycemia (the percentage of days with one or more readings <70 mg/dL, 3.9 mmol/L), and PWDs in Belgium the lowest;
- September 28th was the best day of the year in terms of glycemic control, while January 1st was the worst;
- Valentine’s Day was the holiday PWDs generally experienced the highest average BG, topping Halloween, Christmas Day, and New Year’s Eve;
- PWDs in Australia averaged the most continuous sleep (nights with the least number of interruptions for BG testing), repeating the country’s position in the 2016 report.
“This kind of valuable data collection and analysis allows us to identify broader trends, compare best practices internationally and drive improved care outcomes for people with diabetes on a global scale,” said Dr. Michael Greenfield, Chief Medical Officer of Glooko. “As physicians, we know the value of actionable data on an individual level, but as stewards of public health, we must also consider broader implications for global economics and the research and development community.”
For more information & insights, download the report here.
About Glooko
Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Our self-management mobile app automatically uploads data from devices including blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers – providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. We provide care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, we are used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
©2018 Glooko, Inc. Glooko is a trademark of Glooko, Inc. Other brand names may be trademarks of their respective owner(s). Information is subject to change without notice. All rights reserved. PRM 0466
Growth to over 1.5M patients and 7,000 provider sites, account expansion, published clinical results and a strong fundraise fuel growth
Mountain View, California and Gothenburg, Sweden –January 24, 2018, Glooko, the leader in diabetes data management, today announced that recent growth in its Health System and Payer customer base is driving strong momentum for 2018 and beyond. As the digital health industry matures and such programs are proven to drive both economic and clinical outcomes, Glooko has exhibited strong patient, provider and payer growth. The aggregate results of over 1.5 million people with diabetes (PWDs), 7,000 provider sites using Glooko, and a recent peer reviewed paper published in the Journal of Diabetes Science and Technology all indicate that Glooko is an effective solution for broadly helping PWDs improve outcomes at lower costs.
In 2017, Glooko increased its global provider base by over 2,000 offices to include provider sites such as Fairview Hospitals, The University of Colorado and St. Luke’s. Additionally, Glooko expanded beyond Endocrinology offices to Primary Care Physician (PCPs) offices where the majority of people with type 2 diabetes are served. The company also grew its user base by delivering the platform to two of the largest health insurance carriers in the country, as well as many self-insured employers.
“We love Glooko. It helps our staff go much faster in serving our diabetes population and we look forward to deploying more sites in 2018,” said Jenny Madrid, Program Coordinator at the University of Colorado.
Glooko’s agnostic platform supports most new diabetes devices, including the Ascensia Contour Next One blood glucose meter and Dexcom G5 CGM, increasing Glooko’s compatibility to over 95% of glucose meters, insulin pumps, continuous glucose monitors (CGMs) and activity trackers. New AI-driven features include a pattern detection engine that helps PWDs and care teams understand glucose patterns by day and time of day to drive behavior change. Glooko also submitted its Mobile Insulin Dosing System (MIDS) for FDA clearance and expects such in the first half of 2018. Finally, along with partner Novo Nordisk, Glooko released the Cornerstones 4 Care (C4C) mobile application, an application that combines the award-winning C4C educational content with Glooko’s diabetes management mobile app features.
The $35 million raised in 2017 will help accelerate growth, expand international presence, and deepen expertise in data analytics. This round was led by Georgian Partners, a Toronto-based investor focused on applied analytics and machine learning. Other new investors included Insulet Corporation and Mayo Clinic, who joined Canaan Partners, Social Capital, Medtronic and Samsung NEXT in the round.
With a bold outlook on growth and fuel in the form of financing, new and existing customer and partner growth, and a product roadmap aligned with market needs, Glooko is poised for a strong 2018 and beyond.
About Glooko
Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Our self-management mobile app automatically uploads data from devices including blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers – providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. We provide care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, we are used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com
Glooko MIDS is currently for Investigational Use Only. Limited by Federal (or United States) law to investigational use.
©2018 Glooko, Inc. Glooko and Diasend are trademarks of Glooko, Inc. All rights reserved. PRM 0460 Rev A
Poster on the study to be presented at the Diabetes Technology Society Meeting in Bethesda, MD on November 2-4, 2017
Mountain View, California and Gothenburg, Sweden –October 31, 2017, Glooko, the leader in diabetes data management, announced the results of a feasibility study that examined the impact of Glooko’s product, the Mobile Insulin Dosing System (MIDS) on glycemic control of people with type 2 diabetes on long acting insulin. MIDS is currently available for investigational use only. Insulin management can be an arduous process for a person with diabetes (PWD). In this feasibility study, Glooko evaluated the extent to which its MIDS for long-acting insulin (LAI) dose adjustment can help people with type 2 diabetes, make appropriate titration adjustments, and improve their glycemic status.
A recent study found that PWD are likely to skip insulin injections.[i, ii] Adherence to insulin therapy ranges from 33.2% -77% of people on insulin. [iii],[iv], [v] , [vi] Interestingly, increasing adherence to diabetes medications by 10% is associated with an 8.6% – 28.9% reduction in annual health care costs. [vii] Patients who are adherent to insulin therapy also have lower total healthcare costs although they have higher pharmacy costs. [viii] Ultimately, the goal of the MIDS mHealth application is to improve glycemic outcomes and increase adherence to a long-acting insulin regimen.
“We are thrilled to see early clinical evidence show the positive impact the Glooko Mobile Insulin Dosing System can have on people with diabetes,” said Rick Altinger, CEO of Glooko. “Glooko’s mission has always been to improve clinical outcomes for people with diabetes by making diabetes management easier through digital tools. The potential for improving adherence – and thus improving outcomes and reducing costs – can be invaluable to people with diabetes on long-acting insulin globally.”
The feasibility study, although only for a three week duration, showed that participants experienced the following clinical results as a result of using MIDS:
- Mean Blood Glucose Decrease: The mean blood glucose level of participants decreased on average by 18.2 mg/dL (from 163.9 mg.dL to 145.7 mg/dL; P = .046).
- In-Range Blood Glucose Readings Increase: The proportion of in-range blood glucose readings (defined as 80-180 mg/dL) of participants increased by 9% points from 64.2% to 73.2%; P = .048 on average.
- Reduction in the Rate of Hyperglycemic Events: The percentage of hyperglycemic events (defined as readings >250 mg/dL) of participants decreased from 14.1% of readings to 3.2% of readings; P = 0.029 on average.
- Long-Acting Insulin Dose: The recommended LAI dose increased by 18.7% from the initial dosage by the end of the study period (P = .013) on average.
Every participant but one was already on long-acting insulin, but without the benefit of MIDS prior to the study.
For more information about the results of this study, download the poster from the Glooko resource page after the DTS event or come see our poster presentation at the DTS conference on Friday November 3rd from 4:20-6:30pm in Bethesda, MD.
Glooko MIDS is currently for Investigational Use Only. Limited by Federal (or United States) law to investigational use.
[i] QJM. 2007 ;100(6):345-50. [ii] Diabetes Care. 2010 ;33(2):240-5. [iii] QJM. 2007 ;100(6):345-50. [iv] Patient Prefer Adherence. 2008; 2:87-95. [v] Diabet Med. 2012;29(5):682-9. [vi] Diabetes Care. 2005 ;28(1):78-83. [vii] Clin Ther. 2003 ;25(11):2958-71. [viii] Am Health Drug Benefits. 2015 ;8(3):148-58.
©2017 Glooko, Inc. Glooko and Diasend is a trademark of Glooko, Inc. All rights reserved. PRM 0437 Rev A
Novo Nordisk makes the app available for free
Princeton, New Jersey and Mountain View, California, July 12 2017 –
Novo Nordisk and Glooko have announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes. The C4C mobile app marries Novo Nordisk’s extensive knowledge of diabetes and personalized patient support with Glooko’s digital platform and data analytics expertise. This is the first jointly developed product from the two companies since announcing their collaboration in January 2017.
“For over 90 years, Novo Nordisk has continued to develop innovative diabetes medicines and devices. In today’s environment, in order to truly improve the prospects of the 29 million people with diabetes in the US, we must aspire towards leadership in digital health that complements our research and development expertise,” said David Moore, Senior VP, Marketing for Novo Nordisk Inc. “That was the catalyst to our partnership with Glooko as well as IBM Watson Health and this milestone is just the beginning. Our companies share a common vision of empowering patients with ever improving digital health solutions and we are excited about our combined capabilities and what that can do for improving diabetes treatment.“
Beyond the launch of the C4C app, Novo Nordisk is working with Glooko to enhance its Digital Health Platform – a diabetes management system used to store and analyze data and deliver real-time feedback to people with diabetes and their caregivers. In time, this will contribute to Novo Nordisk’s ability to provide concrete guidance to patients and healthcare professionals and also demonstrate the cost effectiveness of treatments to healthcare systems.
About the Cornerstones4Care Powered by Glooko App
The modular app concept will initially enable people with diabetes to easily measure and track their blood glucose, activity and meals all in one place, and serve as the framework for additional jointly-developed digital tools from Novo Nordisk and Glooko. The C4C App uses Glooko’s cutting-edge technology to sync a user’s blood glucose and activity data from the majority of currently available diabetes and exercise devices. It also identifies pertinent trends to aid in understanding the factors that impact blood glucose levels, and includes relevant content and resources exclusively selected from Cornerstones4Care, the personalized support program for people with diabetes (Cornerstones4Care.com). The integrated offering is intended to help people learn how to better manage diabetes through their mobile devices.
To gain experience and invite use, Novo Nordisk is making the new C4C app free to all patients enrolled in Cornerstones4Care.com and free for download from both the Apple and Google Play App stores. The C4C app represents another milestone in the fast growing Novo Nordisk drive to build its digital health platform, which is being developed in partnership with IBM Watson Health.
Rick Altinger, CEO of Glooko said, “More people than ever are using mobile apps for chronic disease management, and the apps, like the new C4C app, go beyond data capture or tracking to providing insights and recommendations based on that data. By leveraging the expertise and capabilities of Glooko, combined with Cornerstones4Care content, we were able to build a truly unique app to better support people with diabetes.” He added, “Ultimately our digital health solution will help health care practitioners gain round-the-clock insight into their patients, and empower people with diabetes to better manage their diabetes, with the aim of ultimately leading to better diabetes management outcomes.”
About Diabetes
In the United States, more than 29 million people are affected by diabetes. Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases. Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has quadrupled over the past 30 years.
About Novo Nordisk
Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.
About Glooko
Glooko is a leading diabetes data management platform and is trusted by many of the world’s leaders in diabetes care. Over 1 million people with diabetes and 6,000 health systems in 27 countries use Glooko’s FDA-cleared, HIPAA-compliant Mobile, Population Health and Clinic Upload applications with an aim to improve health outcomes for people with diabetes. Glooko syncs with the world’s most popular diabetes devices and major fitness and activity trackers and supplies personalized, timely, verified patient data such as blood glucose, food, insulin, blood pressure, diet and weight data.
For more information visit: glooko.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Novo Nordisk Media:
Susan Jackson (US) +1 609 919 7776 [email protected]
Adam Pittard (Global) +45 3075 5056 [email protected]
Glooko Media:
Jennivine Lee Simon +1 650 720-5310 [email protected]
Novo Nordisk Investors:
Kasper Veje (US) +1 609 235 8567 [email protected]
Glooko Investors:
Michelle de Haaff (Glooko) +1 650 720 5310 [email protected]
PRM 0405 Rev A
Georgian Partners leads growth round
Funds to expand market access and expand data analytics capabilities
MOUNTAIN VIEW, Calif., June 27, 2017 — Glooko, the leader in diabetes data management, today announced $35 million in new funding to accelerate growth, expand international presence, and deepen expertise in data analytics. This round was led by Georgian Partners, a Toronto-based investor focused on applied analytics and machine learning. Other new investors include Insulet Corporation and Mayo Clinic who join existing investors Canaan Partners, Social Capital, Medtronic and Samsung NEXT in the round.
Glooko will use the funds to accelerate growth by expanding its sales, marketing and development teams. The company will also increase commercialization efforts in France, Germany, the U.K., Asia and the Middle East, and further development efforts in data analytics and artificial intelligence to provide personalized insights that drive meaningful behavior change.
“Glooko has demonstrated great traction and growth. Its scalable, device-agnostic platform not only meets the needs of people with diabetes, it also benefits health insurance plans, employers, pharma and health systems that want to effectively manage large populations of people with diabetes,” said Simon Chong, managing director at Georgian Partners. “We are excited to become a part of the Glooko investment team, working with Glooko on its analytics-driven approach to delivering both personal and clinical support to the diabetes community.”
Glooko’s diabetes data management solutions help more than one million patients served by 6,000+ providers and a growing number of health plans around the world. Glooko provides payers, employers, pharmaceutical companies and health systems with a diabetes digital health platform that deliver personalized and actionable insights to people with diabetes and their care teams that aim to drive improved outcomes at a lower cost.
Glooko’s demonstrated improvements in outcomes to manage diabetes are part of a larger effort to combat the growing epidemic. Globally, the cost of diabetes has risen to $825 billion a year and the number of adults with diabetes reached 422 million worldwide in 2016. Without systemic changes to diabetes management, this number could grow to 700 million by 2025, according to a study reported in The Lancet.
“This additional funding will help us to further our mission: to improve the lives of people with diabetes,” said Rick Altinger, CEO of Glooko. “With this capital, we will accelerate our investments in clinical solutions that aim to increase medication adherence, provide personalized insights and prompts that drive behavior change for people with diabetes, and deliver clinical decision support to thousands of clinicians and coaches so they can better support people with diabetes in between office visits.”
About Glooko
More than one million people trust Glooko to help manage their diabetes. Glooko’s FDA-cleared, HIPAA-compliant platform supports more than 6,000 providers in 27 countries. Glooko strives to improve health outcomes with innovations in diabetes data analytics and artificial intelligence. Glooko’s mobile and web apps and clinic upload solutions sync with the world’s most popular diabetes devices, fitness wearables and activity trackers to enable easy data capture and provides reports and analytics that aim to drive behavior change and outcomes. For more information visit: glooko.com,Facebook, Twitter, LinkedIn, YouTube.
About Georgian Partners
Georgian Partners is a thesis-driven growth equity firm investing in SaaS-based business software companies exploiting applied artificial intelligence, security first and conversational business. Founded by successful entrepreneurs and technology executives, Georgian Partners leverages our global software expertise to be able to directly impact the success of companies. For more information, visit www.georgianpartners.com.
Press Contacts
Vikram Singh – [email protected], Glooko, PR
Dana Schroeder – [email protected], Sterling Communications
PRM # 0401
Poster to be presented at the 77th Annual ADA Meeting, June 9-13, 2017 in San Diego, CA
Mountain View, California –June 9, 2017, Glooko, the leader in diabetes data management today announced the results of two retrospective studies that examine the clinical impact of use of its diabetes management mobile application. The studies found that using the Glooko mobile app was associated with a drop in average blood glucose, estimated A1C (eA1C) and hyperglycemia rates in people with diabetes. Furthermore, usage of the Glooko mobile application was also associated with an increase in blood glucose test rate. Increased blood glucose testing rates have been shown to directly correlate with improvements in glycemic control, as evidenced by this retrospective study and other studies as well.
“We are thrilled to see this additional clinical evidence that shows the positive impact Glooko can have on people with diabetes,” Rick Altinger, CEO of Glooko said. “Glooko’s mission has always been to improve the clinical outcomes for people with diabetes by making diabetes management easier through digital tools. Our user satisfaction rates coupled with this clinical evidence adds credence to the investments that digital health companies have been making to improve the lives of people with chronic diseases.”
The Glooko mobile app users in these studies were, on average, already managing diabetes adequately (below 8% eA1c). After starting on Glooko the users showed further improvement. The retrospective studies show that Glooko mobile app users who used the app for self-management experienced the following clinical results compared to a control group of users who did not use the Glooko mobile app, but did upload their data in the clinic:
- Average Blood Glucose: After two months, mobile users experienced an additional 3.54% drop in average BG, over control group users.
- Estimated A1C (eA1C): The studies showed a drop in eA1C among Glooko mobile app users between 0.3% and 0.5% down to 7.14% – 6.98% after two months of using the Glooko mobile app alone.
- Reduction in hyperglycemic rates: Glooko mobile users exhibited an additional decrease in the probability of experiencing hyperglycemic events by 4.38% per month, compared to the control group (p<0.01). Overall, a mobile user could expect a 10.65% decrease in the probability of hyperglycemic events by the end of two months.
- Blood Glucose Test Rate: In addition, there was a statistically significant increase in the average blood glucose test rate of between 16.33% – 34.15% (p<0.01) increase after two months, compared to control.
- Relationship Between Test Rate and Average BG: These increases in blood glucose test rate show a modest but significant correlation to the percent decrease in BG Average (ρ=0.22, p<0.01) indicating that people with diabetes who increased their test rates more, compared to the previous month, also exhibited a decrease in average BG.
For more information about the results of these studies, download the poster presented at the Diabetes Technology Society or come see our most recent poster with updated data at the ADA in San Diego, from June 9-13, 2017 in location 880-P. In addition, Glooko will be demonstrating the Glooko + Diasend integrated product line in booth #2143 at this year’s ADA event.
©2017 Glooko, Inc. Glooko and Diasend is a trademark of Glooko, Inc. All rights reserved. PRM 0400 Rev A
Expanded integration enables on-demand access to CGM data for people with diabetes and care teams to optimize care plans
Mountain View, CA – June 1, 2017, Glooko, the leader in diabetes data management, today announced an expanded agreement with Dexcom, the leader in Continuous Glucose Monitoring (CGM) for people with diabetes. Rather than requiring Dexcom devices to be proactively synced to Glooko via a cable or connection to Apple Health, this expanded relationship will deliver Dexcom CGM data from all currently available Dexcom CGM systems into Glooko’s platform via the cloud. The cloud integration empowers people with diabetes and their care teams to optimize diabetes support by enabling passively collected, on-demand access to CGM data through the widely used Glooko platform.
“With this expanded relationship and ease of delivering Dexcom CGM data into Glooko, clinicians have additional options available to make better and faster treatment decisions,” said Steve Pacelli, Executive Vice President of Strategy and Corporate Development, Dexcom. “Glooko’s extensive clinical presence and use by people with diabetes globally make it an obvious choice to strengthen our partnership.”
Dexcom’s cloud infrastructure is designed to give people with diabetes easy access to their CGM data and control over who they share it with, so they can enhance both their self-management and clinic-based care. This relationship builds on Glooko’s continued dedication to liberating diabetes data to help improve daily decision making for people with diabetes and their care teams.
“We are thrilled to expand our partnership with Dexcom and provide our over 6,000 clinic users and 1 million patients globally better and faster access to their Dexcom CGM data,” said Rick Altinger, CEO, Glooko. “Having Dexcom CGM data, combined with food, medication and exercise data in Glooko, enables us to pinpoint behaviors and personalize insights to drive behavior change and ultimately improved outcomes.”
Dexcom G5 Mobile CGM data will be available for patients to sync to Glooko this summer and via Glooko’s Office Upload products (The Glooko Kiosk, The Glooko Clinic Uploader and the Glooko Transmitter) in the US this month. It is already available in the EU through Glooko’s office upload product, Diasend. The expanded cloud integration with Dexcom will be available globally later this year in Glooko.
For more information visit: glooko.com, Facebook, Twitter, LinkedIn, YouTube.
PRM 0399
Partnership to marry technology platform with human coaching, aims to improve outcomes for patients and care teams
Mountain View & New York, New York, California, April 27, 2017 – Fit4D, a diabetes patient engagement solution, announced a partnership today with Glooko, a global diabetes data management company, to deliver highly personalized, data-driven coaching and a mobile health solution to patients and care providers.
The Glooko/Fit4D collaboration, which leverages user-specific data for timely and customized interventions, aims to improve health outcomes, reduce costs, and enhance patient-coach relationships. Combining Fit4D’s clinically expert coaches with Glooko’s device agnostic technology platform creates one of the marketplace’s most scaleable, integrated diabetes management offerings.
“We always look for ways to deliver better support to our patients, so we are excited to partner with Glooko,” said David Weingard, CEO of Fit4D. “Glooko’s mobile solution, providing access to glycemic data, complemented with contextualized lifestyle tracking, provides Fit4D even more insight into how our patients are doing so we can provide them with the support they need, when they need it most.” Weingard shares, “With the Glooko collaboration, Fit4D can offer a comprehensive patient engagement solution that delivers on positive patient experience, an opportunity to strengthen brand loyalty for our pharma clients, while creating value to payers, providers, and employers seeking to provide services to individuals with chronic diseases, like diabetes.”
Glooko enables Fit4D to extend the impact of personal coaching through data and insights while Fit4D provides Glooko patients and clients with the turnkey “human touch” component that drives sustained behavior change. Glooko’s mobile app enables people with diabetes to automatically sync their blood glucose data from over 95% of the blood glucose meters, CGMs and insulin pumps available on formulary and then augment that data with food, exercise and medication data. That data is then made available to Fit4D coaches through the Glooko Population Tracker.
With the support of Fit4D clinical educators, patients will receive additional motivation and education to engage more meaningfully with the Glooko platform – from how to sync their data to understanding what their data means to them.
“Fit4D’s depth of clinical experience and years of diabetes expertise extends the value of the Glooko diabetes management platform and offers organizations without coaching an integrated diabetes management solution,” said Rick Altinger, CEO of Glooko. “Combining the quantitative data from Glooko with the expert coaching and qualitative data on patient barriers and confidence from Fit4D allows us to jointly provide a flexible end-to-end solution that provides important and relevant support to people with diabetes.”
Fit4D is a technology-enabled health coaching solution that scales the ability of expert certified diabetes educators (CDEs), to reach and engage patients. Fit4D clients include pharmaceutical companies with a branded drug or device seeking to improve initiation and adherence, and payers looking to improve health outcomes and quality measures.
The company’s team of CDEs across the country leverage the Fit4D technology platform to engage patients with personalized plans that address the individual barriers one faces when learning to self-manage the condition. Coaching topics include diabetes education, tips and tactics to initiate therapy and improve medication adherence, the importance of preventive care, nutrition, exercise, advice to overcome psychosocial barriers, weight management and more.
Glooko’s diabetes management solution offers mobile and web based tools that sync with patients’ preferred diabetes devices – no switching needed. Powerful algorithms that identify important glucose trends and the ability to correlate the impact of food, activity and other lifestyle choices on glucose values give Glooko patients and the thousands of care teams who use Glooko, the insights they need to make better decisions.
About Fit4D
Fit4D’s mission is to enrich the lives and the improve health outcomes of people living with diabetes and other chronic diseases worldwide. Fit4D delivers scalable and cost-effective personalized patient programs using a technology platform to optimize the mix of digital and human-based touch points. The Fit4D clinical team of certified diabetes educators (CDEs) is comprised of dietitians, exercise physiologists, nurses, and social workers, who are passionate about empowering people with diabetes to live rich, healthy and fulfilling lives.
Fit4D’s Fortune 500 clients include pharmaceutical, payer, provider and wellness companies. Fit4D has also engaged in numerous joint initiatives with the Juvenile Diabetes Research Foundation, American Diabetes Association, and the Diabetes Research Institute.
Fit4D is also a Startup Health transformer company. For more information, visit: www.fit4d.com.
About Glooko
Glooko is the leading diabetes management solution and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offer diabetes-centric analytics and insightful reports, graphs and risk flags to health systems and payers. For more information, visit: www.glooko.com
PRM 0370
Basel, Switzerland and Mountain View, CA 31 January 2017 – Ascensia Diabetes Care and Glooko, Inc today announced a global technology partnership designed to bring together their state-of-the-art diabetes management solutions, and improve diabetes data management and analytics. This collaboration includes integration of Glooko’s Diabetes Data Management Platform and Ascensia’s CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems. The integration of these solutions will allow people with diabetes and health care professionals to access and analyze highly accurate blood glucose data at home, on the move and during office visits through the digital platform of their choice.
“Glooko’s Diabetes Data Management Platform has become widely used for both personal and clinical diabetes data analytics and decision support,” said Michael Kloss, CEO of Ascensia Diabetes Care. He continued, “Glooko’s broad distribution into health systems will enable us to easily and seamlessly deliver highly accurate data from our CONTOUR NEXT®ONE and CONTOUR®PLUS ONE blood glucose monitoring systems to clinicians right in their workflow. By linking our systems to Glooko’s Diabetes Data Management Platform, we want to enable better understanding and analysis of diabetes data, and ultimately help to improve the lives of people with diabetes.”
The integration of these solutions will allow blood glucose data to be accessed by Glooko’s Mobile App and Clinic Data Upload products directly from the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE meters via Bluetooth® connectivity and through an automatic feed via the CONTOUR CLOUD. People with diabetes will be able to view their data both in Glooko’s Mobile and Web Apps, as well as in the CONTOUR™ DIABETES App from Ascensia. Health care professionals will be able to seamlessly access data from these two Ascensia systems in a way that fits directly into their workflow via the Glooko Clinic Solution.
“The usability and accuracy of the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems from Ascensia Diabetes Care is impressive and we are excited to bring this rich data into the Glooko platform to help both people with diabetes and their health care professionals manage this condition,” said Rick Altinger, Glooko CEO.
The CONTOUR®NEXT ONE system recently received 510(k) clearance from the FDA and Ascensia Diabetes Care expects to make this system available in the United States in early 2017. The CONTOUR™ DIABETES app will be available for download from the Apple App Store (iOS) and Google Play (Android). The CONTOUR®NEXT ONE and CONTOUR®PLUS ONE systems have been demonstrated to be the two most accurate systems developed by Ascensia Diabetes Care to date, having been shown to deliver remarkable accuracy. In a clinical study, 95% of blood glucose results obtained with CONTOUR®NEXT ONE were within 8.4 mg/dL (0.5 mmol/L) or 8.4% of the reference result for subject fingertip tests.1 In a similar clinical study, 95% of blood glucose results for CONTOUR®PLUS ONE were within 8.5 mg/dL (0.5 mmol/L) or 8.5% of the reference result for subject fingertip tests.2
Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Glooko’s award-winning mobile health app enables individuals to synchronize their data from a majority of the world’s most popular diabetes and exercise devices including blood glucose meters. Glooko’s population health application enables care teams to remotely support people with diabetes and aims to improve patient satisfaction and outcomes at a lower cost.
This global agreement covers all markets where Glooko and these Ascensia systems are available. The integration between these two solutions is expected to be available for people with diabetes and health care professionals later in 2017.
ENDS
Notes for Editors
About Glooko
Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Over 4,800 health systems in 27 countries use Glooko’s FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes and to enable diabetes population health for providers. Glooko seamlessly syncs with the world’s most popular diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. For more information visit: glooko.com, Facebook, Twitter, LinkedIn, YouTube.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.
Home to the world renowned CONTOUR™ portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 38 countries.
For further information please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.
2017 Ascensia Diabetes Care. Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. Glooko is a registered trademark of Glooko, Inc.
The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license.
Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Google Play is a trademark of Google Inc.
For more information please contact:
Joseph Delahunty, VP, Global Head of Communications
Ascensia Diabetes Care
E-mail: [email protected]
Phone: +41 79 422 9286
Vikram Singh, Marketing Manager
Glooko
E-mail: [email protected]
Phone: +1 650 720 5310
References
1.Christiansen et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.
2.Bailey et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.